<DOC>
	<DOCNO>NCT00642967</DOCNO>
	<brief_summary>This single arm study ass efficacy safety monthly administration subcutaneous Mircera administer maintenance hemoglobin level patient chronic renal anemia , dialysis . Patients currently receive treatment subcutaneous epoetin darbepoetin alfa receive monthly subcutaneous injection Mircera , start dose ( 120 200 microgram ) calculate last weekly dose ESA previously administer . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera For The Maintenance Treatment Anemia Patients With Chronic Kidney Disease Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic kidney disease stage 3 4 , chronic renal anemia , require dialysis ; continuous stable subcutaneous maintenance ESA therapy previous month . transfusion red blood cell previous 2 month ; significant acute chronic bleeding ; poorly control hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>